Original Article | Published:

Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide

Journal of Human Hypertension volume 13, pages 559563 (1999) | Download Citation



Objectives: To compare quality of life with the selective β1-blocker bisoprolol and the thiazide diuretic bendrofluazide in patients with mild to moderate hypertension. Design and setting: Multi centric, randomised, double-blind, two-way crossover study carried out at six general practice centres. Subjects: Eighty-one patients with newly diagnosed or previously treated hypertension, who had a mean diastolic blood pressure (BP) of 95–120 mm Hg after receiving placebo for 4–6 weeks. Interventions: In random order, patients received bisoprolol (5 mg once daily) or bendrofluazide (2.5 mg once daily) for 8 weeks. Main outcome measures: Quality of life and antihypertensive effect. Results: Decrease in systolic/diastolic BP did not differ between bisoprolol (10 ± 2/13 ± 1 mm Hg) and bendrofluazide (9 ± 2/11 ± 1 mm Hg). Between bisoprolol and bendrofluazide neither in the intention-to-treat nor in the efficacy analysis any difference was found in quality of life variables, such as Health Status Index, somatic symptoms, anxiety, depression, total psychiatric morbidity, cognitive symptoms and hostility score. Compared to baseline the Health Status Index improved (P < 0.05) during bisoprolol. none of the other investigated quality of life variables changed compared to baseline. no patients dropped out during bisoprolol or bendrofluazide treatment. although, the total number of reported adverse events appeared lower during bendrofluazide than during bisoprolol treatment, it is unclear whether drug related adverse events also differ between the two drugs. Conclusions: At equipotent antihypertensive dosages, the effect of an 8-week treatment on quality of life does not differ between the selective β1-blocker bisoprolol and the thiazide diuretic bendrofluazide.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Author information


  1. Department of Pharmacology, Maastricht University, Cardiovascular Research Institute Maastricht (CARIM), PO Box 616, 6200 MD, Maastricht, The Netherlands

    • FHM Vanmolkot
    • , JNJM de Hoon
    •  & LMAB Van Bortel
  2. Medical Department, E Merck, PO Box 8198, 1005 AD, Amsterdam, The Netherlands

    • LLM van de Ven


  1. Search for FHM Vanmolkot in:

  2. Search for JNJM de Hoon in:

  3. Search for LLM van de Ven in:

  4. Search for LMAB Van Bortel in:

Corresponding author

Correspondence to LMAB Van Bortel.

About this article

Publication history






Further reading